Hot Investor Mandate: Life Sciences Investment Firm with Over $1B+ AUM Invests in Therapeutics, Devices, Diagnostics, Digital Health, and Drug Discovery & Research Tools

15 Nov

A life sciences investment firm with a global diversified strategy ranging from seed stage to public companies, is actively involved in innovation, restructuring opportunities, and growth investing. The firm’s investment team brings a wealth of experience across all areas of the life sciences industry. Nearly all of the firm’s partners have been with the firm for 12 years or more, and they are supported by over 20 investment professionals, distinguished advisers, and scientific advisory board members. The firm has no set number of allocations that it plans to make but is actively reviewing new opportunities from around the globe. The firm has a history of strategic relationships with other venture capital firms or funds targeting specific sectors or geographies within the life sciences. These working relationships help give them a global footprint and vastly expand the firm’s deal flow.

The firm’s general life sciences funds represent approximately $1.3 billion in capital commitments. These funds target a diverse group of life sciences companies, across all stages of development. Bay City Capital funds have invested in a total of 100 portfolio companies covering a broad range of life science sectors, including biopharmaceuticals, drug discovery and research tools, medical devices, diagnostics, digital health, nutrition, and agribusiness.

The firm seeks to invest its capital in life sciences companies where their operational, financial, and scientific expertise can assist management in building companies. This investment approach has remained largely consistent since 1997, delivering attractive returns to their investors. Effective management is critical to the success of their portfolio companies. The firm assists their portfolio companies in recruiting and retaining key management and advisors, identifying product opportunities, establishing and negotiating strategic partnerships, and providing assistance with product development and execution. The firm develops close working relationships with their management teams to establish themselves as true partners in business building.

The firm strongly prefers board representation, and have received a board seat with 90% of their portfolio companies (based on invested capital). The firm believes this commitment of intellectual capital increases the likelihood of positive outcomes for their investments, and has established them as a preferred partner in the industry.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: